2022 TRENDS IN BIOSIMILARS REPORT PREVIEW
CONTENTS

- Trends in US Biosimilar Approvals and Launches
- Timeline of Approved Biosimilars and Launch Dates
- Trends in Pricing, Uptake, and Total Drug Spend
- The Future of Biosimilars
- Boxed Warnings for Amgen Products

This is a preview of the full TRENDS IN BIOSIMILARS REPORT anticipated for release in Q3 2022
The US marketplace is poised to see growth in biosimilar approvals, similar to pre-pandemic rates, spurring additional competition that will potentially lead to significant savings for the healthcare system, which can then be deployed to newer, innovative treatments.¹

Essential components of provider and patient use of biosimilars include payer coverage as well as addressing the clinical, operational, and economic considerations to help support adoption. Given the new therapeutic areas and types of biosimilars that will be available in the next few years, provider and pharmacist education will be critical as well.

While financial savings are important for helping support biosimilar uptake, it is not the only consideration for payers and providers. Other factors include manufacturer reputation for producing high-quality products; reliably supplying these products; and understanding provider and payer clinical, economic, operational, and decision-making drivers.

“Current State of the Marketplace”

Key: US – United States.

We anticipate biosimilars in 2022 to continue the promise of cost savings and increased access to patients. This year will prove pivotal for the pharmacy benefit space, as providers and pharmacists navigate the first interchangeable biosimilar insulin listed as preferred on several national formularies.

— Beth McMahon
Senior Vice President, Emerging Therapies & Channel Strategy, AmerisourceBergen
THE US MARKETPLACE FOR BIOSIMILARS IS NOW WELL-ESTABLISHED AND ACCELERATING ACROSS MULTIPLE THERAPEUTIC AREAS

Figure 1 shows the number of biosimilars approved and launched each year from 2015 to 2022. There was a dramatic increase in biosimilar launches from 2018 to 2020 compared to prior years.²

The slowdown of biosimilar approvals in 2020 and 2021 was likely due to several factors, some of which were pandemic-related. Over the next few years, the biosimilars marketplace should recover from this decline in activity, with new approvals and launches expected to increase at pre-2020 rates.

Figure 1. Number of Approved and Launched Biosimilars in the US, per Year²

Although there was an overall decline in the number of approvals during the 2020 to 2021 timeframe, the number of development programs that are participating in the FDA’s Biosimilar Development Program has continued to rise³:

- 77 programs in March 2019
- 79 programs in March 2020
- 90 programs in March 2021
- 97 programs in December 2021†

Key: BLA – Biologics License Application; FDA – Food and Drug Administration; US – United States.
*2022 totals include latest available information (January to May 2022).
†Program totals reflect latest available data.
Note: SEMGLEE® (insulin glargine-yfgn) was approved by the FDA in June 2020 with a stand-alone BLA. The FDA subsequently approved SEMGLEE as an interchangeable biosimilar in July 2021.⁴,⁵
THE US BIOSIMILAR LANDSCAPE IS ADVANCING FASTER THAN THE EU BIOSIMILAR LANDSCAPE DURING A COMPARABLE PERIOD OF TIME

Figure 2 shows the cumulative number of biosimilars approved in the EU vs the US, beginning with the year the first biosimilar was approved.6,7 The slowdown in EU approvals between years 4 and 7 was likely due to several factors that may include intellectual property timelines and duration of development programs.

In the 8 years after the EU approved the first biosimilar (2006), there were 15 approved biosimilars.7

By contrast, in the 8 years after the US approved the first biosimilar (2015), there were 36 approved biosimilars.6

Figure 2. Comparison of Cumulative Approved Biosimilars in the EU and the US6,7

Key: EU – European Union; US – United States.
*Year 8 includes US approvals and launches through May 2022.
TIMELINE OF APPROVED BIOSIMILARS AND LAUNCH DATES

As of May 2022, the FDA has approved 36 biosimilars and 21 biosimilars have been launched in the US as shown in Figure 3. Currently, there are 11 reference products that have approved biosimilars.

FDA Approval
Launch
FDA Approved but Not Commercially Available

Figure 3. Approved and Launched Biosimilars (including GRANIX®) in the US

Please see slides 11-15 for Boxed Warning information for AVSOLA, EPOGEN, Enbrel, KANJINTI, and RIABNi.

Key: BLA – Biologics License Application; FDA – Food and Drug Administration; US – United States.

*GRANIX is not a biosimilar. It was approved under a stand-alone BLA, which was submitted to the FDA before the enactment of the biosimilar approval pathway.
†SEMGLEE was approved by the FDA in June 2020 with a stand-alone BLA. The FDA subsequently approved SEMGLEE as an interchangeable biosimilar in July 2021.
BIOSIMILARS LAUNCH WITH SIGNIFICANT DISCOUNTS TO WAC AND ASP

Biosimilars are helping reduce healthcare costs by providing significant wholesale acquisition cost (WAC) and average sales price (ASP) savings at launch and through price competition, resulting in the opportunity for additional savings over time.

As shown in Figure 4, manufacturers are launching biosimilars at a WAC that is generally lower than the reference product (biosimilars' ASP becomes available 2 full quarters after launch).8

Biosimilar WAC vs Reference Product ASP:
Almost all biosimilars have launched at a WAC of 3% to 24% below the reference product ASP.

Biosimilar WAC vs Reference Product WAC:
Biosimilars launch at a WAC that is generally 15% to 37% lower than the reference product.

Please see slides 11-15 for Boxed Warning information for AVSOLA, EPOGEN, Enbrel, KANJINTI, and RIABNI.

Key: ASP = average sales price; Bio = biosimilar; FDA = Food and Drug Administration; RP = reference product; WAC = wholesale acquisition cost.

*GRANIX is not a biosimilar. It was approved under a stand-alone Biologics License Application, which was submitted to the FDA before the enactment of the biosimilar approval pathway.

Source: AnalySource.
ASP s ARE DECLINING FOR BOTH REFERENCE AND BIOSIMILAR PRODUCTS

As expected, competition usually results in lower ASP for both reference products and biosimilars, leading to additional savings. As shown in Figure 5, in most cases, the prices of biosimilars decline once ASP is established and continue a steady downward trend. The ASPs for reference products are also declining over time, leading to further opportunity for healthcare savings.

Figure 5. Downward Trend in ASP for Biosimilars and Reference Products Over Time

The prices of biosimilars are decreasing at a CAGR of 9% to 22%.

The prices of most reference products* are decreasing at a CAGR of 4% to 20%.

Please see slides 11-15 for Boxed Warning information for AVSOLA, EPOGEN, Enbrel, KANJINTI, and RIABNI.

Key: ASP = average sales price; CAGR = compound annual growth rate; FDA = Food and Drug Administration.

*NEUPOGEN®’s biosimilar price-response strategy focused on account-level provider contracting. This targeted approach modestly increased the ASP-eligible discount rate resulting in a more stable ASP trend.

**Additional research is being conducted to understand the recent spikes in ONTRUZANT and RENFLEXIS.

†GRANIX is not a biosimilar. It was approved under a stand-alone Biologics License Application, which was submitted to the FDA before the enactment of the biosimilar approval pathway.

Source: AnalySource.
The rate of biosimilar uptake is generally increasing over time, as depicted in Figure 6. Biosimilars have gained significant share in the majority of therapeutic areas where they have been introduced. Additionally, first-to-launch biosimilars tend to capture a greater portion of the segment compared to later entrants.

For therapeutic areas with biosimilars launched in the last 3 years, the average share was 74%.

For therapeutic areas with biosimilars launched prior to 2019, the average share after 3 years was 38%.

**Figure 6. Biosimilars Uptake Curve**

Key: ESA = erythropoiesis-stimulating agent.
BIOSIMILAR COMPETITION APPEARS TO BE CONTRIBUTING TO DECREASED DRUG SPENDING

Figure 7 shows the estimated decrease in total drug spend after biosimilar competition was introduced. Change in drug spend shown is the delta between the projected reference product spend (based on historical trend) vs the actual spend following biosimilar launch. Beginning in Q1 2019, drug spending for most classes continues to decrease.

The cumulative savings in drug spend for classes with biosimilar competition is estimated to have been $18 billion over the past 6 years.

Trends show an increase in savings per quarter, and in Q1 2022 alone, savings in drug spend are estimated to be $3 billion.

Figure 7. Estimated Change in Total Drug Spend After Biosimilar Competition

Key: ASP – average sales price.
Note: Filgrastim is excluded from figure because the first biosimilar in its class was launched in 2013 and data are not available prior to Q2 2016 for normalized units.

The quarterly drug spend for each product is estimated as: Drug spend=ASPxNormalized unit volume. The estimated spend for the reference product (after biosimilar launch) is trended out based on historical spend for the reference product before biosimilar launch.

Sources: AnlySource, Integrated Weekly Sales Data (IQVIA DDD + Chargeback).
THE FUTURE OF BIOSIMILARS

Biosimilars are expanding into new areas

Over the next few years, the growing number of biosimilars will likely lead to a rapid evolution in the US biosimilars marketplace, including:

- Expansion of biosimilars into pharmacy benefit reimbursement
- Biosimilars in more therapeutic areas (autoimmune, oncology, endocrinology)
- Approval of additional interchangeable biosimilars in the US
- Focus on provider education and comfort with prescribing and using biosimilars
- Use of market and regulatory trends outside the US
- Use of real world evidence to inform the future of the marketplace

These changes are likely to cement the role of biosimilars as viable and integral US treatment options. Biosimilars will find new audiences in different prescriber specialties, pharmacists, payers, and patients. These developments may change the patient support program landscape, interactions at the pharmacy counter, and product-administration devices.

Key: US — United States.
ANTICIPATED ENTRY OF HUMIRA BIOSIMILARS ARE EXPECTED TO INCREASE COMPETITION FOR A TOP-SELLING AUTOIMMUNE DRUG IN THE US

As shown in Table 1, there are currently 7 FDA-approved biosimilars for the reference product HUMIRA, with the possibility of 7 or more launches in 2023. Based on the history of pricing for biosimilar and reference products seen in other areas, the entry of additional biosimilars is expected to lead to greater price declines across all products within the class.

Table 1. Launch Dates of Biosimilars HUMIRA as Agreed in Settlements with HUMIRA Manufacturer AbbVie2,7,12-15

<table>
<thead>
<tr>
<th>Company</th>
<th>Drug</th>
<th>FDA approved</th>
<th>Anticipated US launch*</th>
<th>Launched in the EU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amgen</td>
<td>AMJEVITA†</td>
<td>✓</td>
<td>January 31, 2023</td>
<td>✓</td>
</tr>
<tr>
<td>Samsung Bioepis/Merck</td>
<td>HADLIMA‡</td>
<td>✓</td>
<td>June 30, 2023</td>
<td>✓</td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
<td>CYLTEZO</td>
<td>✓</td>
<td>July 1, 2023</td>
<td>✓</td>
</tr>
<tr>
<td>Coherus BioSciences</td>
<td>YUSIMRY</td>
<td>✓</td>
<td>July 1, 2023</td>
<td></td>
</tr>
<tr>
<td>Mylan</td>
<td>HULIO</td>
<td>✓</td>
<td>July 31, 2023</td>
<td>✓</td>
</tr>
<tr>
<td>Sandoz</td>
<td>Hyrimoz</td>
<td>✓</td>
<td>September 30, 2023</td>
<td>✓</td>
</tr>
<tr>
<td>Pfizer</td>
<td>ABRILADA</td>
<td>✓</td>
<td>November 20, 2023</td>
<td>✓</td>
</tr>
<tr>
<td>Fresenius Kabi</td>
<td>IDACIO</td>
<td></td>
<td>September 30, 2023</td>
<td>✓</td>
</tr>
<tr>
<td>Celltrion</td>
<td>Yuflyma</td>
<td></td>
<td>July 2023</td>
<td>✓</td>
</tr>
<tr>
<td>Alvotech§</td>
<td>AVT02</td>
<td></td>
<td>N/A</td>
<td>✓</td>
</tr>
</tbody>
</table>

Data current as of Q1 2022.
Key: EU – European Union; FDA – Food and Drug Administration; US – United States.
*Companies may launch earlier than their settlement date.
†AMJEVITA is marketed as AMGEVITA in the EU.
‡HADLIMA is marketed as IMRALDI in the EU and manufactured/marketed by Samsung Bioepis/Biogen.
§STADA Arzneimittel AG has exclusive commercialization rights to AVT02 in all key European markets under names HUKYNDRA and LI BMYRIS.
BOXED WARNINGS

AVSOLA®

WARNING: SERIOUS INFECTIONS and MALIGNANCY

See full Prescribing Information for complete boxed warning.

• Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis) and infections due to other opportunistic pathogens. (5.1)
• Discontinue AVSOLA if a patient develops a serious infection.
• Perform test for latent TB; if positive, start treatment for TB prior to starting AVSOLA. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. (5.1)
• Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including infliximab products. (5.2)
• Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers including infliximab products. Almost all had received azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. The majority of cases were reported in patients with Crohn's disease or ulcerative colitis, most of whom were adolescent or young adult males. (5.2)
BOXED WARNINGS (cont.)

EPOGEN®

WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE

See full Prescribing Information for complete boxed warning.

Chronic Kidney Disease:

* In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL (5.1).
* No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks (2.2).

Cancer:

* ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers (5.2).
* Use the lowest dose to avoid RBC transfusions (2.4).
* Use ESAs only for anemia from myelosuppressive chemotherapy (1.3).
* ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure (1.5).
* Discontinue following the completion of a chemotherapy course (2.4).

Perisurgery:

* Due to increased risk of Deep Venous Thrombosis (DVT), DVT prophylaxis is recommended (5.1).
<table>
<thead>
<tr>
<th>BOXED WARNINGS (cont.)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WARNINGS: SERIOUS INFECTIONS AND MALIGNANCIES</strong></td>
</tr>
<tr>
<td>See full <a href="#">Prescribing Information</a> for complete boxed warning.</td>
</tr>
</tbody>
</table>

**SERIOUS INFECTIONS**

- Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. (5.1)
- Enbrel should be discontinued if a patient develops a serious infection or sepsis during treatment. (5.1)
- Perform test for latent TB; if positive, start treatment for TB prior to starting Enbrel. (5.1)
- Monitor all patients for active TB during treatment, even if initial latent TB test is negative. (5.1)

**MALIGNANCIES**

- Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including Enbrel. (5.3)
**BOXED WARNINGS (cont.)**

**KANJINTI®**

**WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY**

See full Prescribing Information for complete boxed warning.

Cardiomyopathy: Trastuzumab products can result in subclinical and clinical cardiac failure manifesting as CHF, and decreased LVEF, with greatest risk when administered concurrently with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue KANJINTI for cardiomyopathy. (2.3, 5.1)

Infusion Reactions, Pulmonary Toxicity: Discontinue KANJINTI for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome. (5.2, 5.4)

Embryo-Fetal Toxicity: Exposure to trastuzumab products during pregnancy can result in oligohydramnios, in some cases complicated by pulmonary hypoplasia and neonatal death. Advise patients of these risks and the need for effective contraception. (5.3, 8.1, 8.3)

**RIABNI™**

**WARNING: FATAL INFUSION-RELATED REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEukoencephalopathy**

See full Prescribing Information for complete boxed warning.

- Fatal infusion-related reactions within 24 hours of rituximab infusion; approximately 80% of fatal reactions occurred with first infusion. Monitor patients and discontinue RIABNI infusion for severe reactions (5.1).
- Severe mucocutaneous reactions, some with fatal outcomes (5.2).
- Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death (5.3).
- Progressive multifocal leukoencephalopathy (PML) resulting in death (5.4).
REFERENCES


10. Data on file, Amgen; Reference Product and Biosimilar Share Trends; April 2022.

11. Data on file, Amgen; Biosimilars Spend Analysis; April 2022.


